Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 6, 1999, Pages 782-790

  Trippodo, Nick C ^a,b   Fox, Maxine ^a   Monticello, Thomas M ^a   Panchal, Balkrushna C ^a   Asaad, Magdi M ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Angiotensin; Heart failure; Hemodynamics; Mortality; Natriuretic peptides

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME INHIBITOR; OMAPATRILAT; UNCLASSIFIED DRUG; VASOPEPTIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; HAMSTER; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE VOLUME; HEART PROTECTION; HEART WEIGHT; LUNG CONGESTION; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD VESSELS; CAPTOPRIL; CARDIOMYOPATHY, DILATED; CRICETINAE; HEMODYNAMIC PROCESSES; MALE; MYOCARDIUM; PROTEASE INHIBITORS; PYRIDINES; SURVIVAL ANALYSIS; THIAZEPINES;

EID: 0032734821     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199912000-00003     Document Type: Article

References (33)

1. Flynn GA, French JF, Dage RC. Dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase: design and therapeutic rationale. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press, 1995:3099-114.
2. Robl JA, Trippodo NC, Petrillo EW. Neutral endopeptidase inhibitors and combined inhibitors of neutral endopeptidase and angiotension-converting enzyme. In: Van Zwieten PA, Greenlee WJ, eds. Antihypertensive drugs. Amsterdam: Harwood Academic Publishers, 1997:113-212.
3. The Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J 1997;18:736-53.
4. Cushman DW, Cheung HS, Sabo EF, Ondetti MA. Design of potent competitive inhibitors of angiotensin-converting enzyme: carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 1977;16:5484-91.
5. Dargie HJ, McMurray JJV, McDonagh TA. Heart failure - implications of the true size of the problem. J Intern Med 1996; 239:309-15.
6. Remme WJ. Neurohormonal modulation in heart failure: ACE inhibition and beyond. Eur Heart J 1995;16(suppl N):73-8.
7. Sigurdsson A, Swedberg K. The role of neurohormonal activation in chronic heart failure and postmyocardial infarction. Am Heart J 1996;132(suppl):229-34.
8. Cleland JGF, Cowburn PJ, Struthers AD. Neutral endopeptidase inhibitors: effects on peptide metabolism and potential therapeutic use in the treatment of heart failure. Heart Failure 1996;12:73-92.
9. Abraham WT. Physiology and therapeutic implications of natriuretic peptides in heart failure. Heart Failure 1996;12:55-72.
10. Margulies KB, Perrella MA, McKinley U, J C Burnett J. Angiotensin inhibition potentiates the renal response to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest 1991;88:1636-42.
11. Seymour AA, Asaad MM, Lanoce VM, Langenbacher KM, Fennell SA, Rogers WL. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 1993; 266:872-83.
12. Trippodo NC, Fox M, Natarajan V, Panchal BC, Dorso CR, Asaad MM. Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure. J Pharmacol Exp Ther 1993;267:108-16.
13. Favrat B, Bumier M, Nussberger J, et al. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 1995;13:797-804.
14. Newby DE, McDonagh T, Currie PF, Northridge DB, Boon NA, Dargie HJ. Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition [Abstract]. Heart 1997;77:P29.
15. Trippodo NC, Panchal BC, Fox M. Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure. J Pharmacol Exp Ther 1995;272:1-9.
16. Trippodo NC, Robl JA, Asaad MM, et al. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther 1995;275:745-52.
17. Kirk JE, Wilkins MR. Renal effects of concurrent E-24.11 and ACE inhibition in the aorto-venocaval fistula rat. Br J Pharmacol 1996;119:943-8.
18. Chatelain RE, Ghai RD, Trapani AJ, et al. Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11. J Pharmacol Exp Ther 1998;284:974-82.
19. Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 1998;11:363-72.
20. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
21. Pfeffer MA, Pfeffer JM, Steinberg CS, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985;72:406-12.
22. Haleen SJ, Weishaar RE, Overhiser RW, et al. Effects of quinapril, a new angiotensin converting enzyme inhibitor, on left ventricular failure and survival in the cardiomyopathic hamster. Circ Res 1991;68:1302-12.
23. Barnes PE, Hanton G, Samuels GMR, Shepperson NB. Candoxatril, an orally active inhibitor of neutral endopeptidase, increases survival in cardiomyopathic hamsters [Abstract]. Eur Heart J 1992;13:240.
24. McClean D, Ikram H, Melton I, et al. Cardiac, renal and endocrine effects of three month treatment of chronic heart failure with the vasopeptidase inhibitor, omapatrilat [Abstract]. J Am Coll Cardiol 1999:33(suppl A):185A.
25. Teerlink JR, Pfeffer JM, Pfeffer MA. Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ Res 1994;75:105-13.
26. Raya TE, Gay RG, Aguirre M, Goldman S. Importance of venodilation in prevention of left ventricular dilatation after chronic large myocardial infarction in rats: a comparison of captopril and hydralazine. Circ Res 1989;64:330-7.
27. Erdos EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989; 3:145-51.
28. Gertz EW. Cardiomyopathic Syrian hamster: a possible model of human disease. Prog Exp Tumor Res 1972;16:242-60.
29. Sole MJ. Hamster cardiomyopathy: understanding the pathogenesis of heart failure. Hamster Information Service 1986;8:3-6.
30. Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: results of the SOLVD echocardiography substudy. Circulation 1995;91:2573-81.
31. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
32. Thomas CV, McDaniel GM, Holzgrefe HH, et al. Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs. J Cardiovasc Pharmacol 1998;32:902-12.
33. Marie C, Mossiat C, Gros C, Schwartz J, Lecomte J, Bralet J. Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction. Cardiovasc Res 1999;41:544-53.